Molecular Genetics & Genomic Medicine · 2021 · 22 citations · 30 references
MedicineOncologyPharmacologyCell SignalingGene ExpressionMolecular PharmacologyNuclear Receptor SignalingNuclear ReceptorsAcute Myeloid Leukemia TherapyCancer Cell Survival SignalingNuclear Receptor PharmacologyPeroxisome Proliferator Receptor SignalingPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated Receptors
BACKGROUND: In the new era of tailored cancer treatment strategies, finding a molecule to regulate a wide range of intracellular functions is valuable. The unique property of nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ; PPARG) in transmitting the anti-survival signals of the chemotherapeutic drugs has fired the enthusiasm into the application of this receptor in cancer treatment. OBJECTIVES: We aimed to investigate the expression of PPARγ and one of its downstream targets PTEN in non-M3 acute myeloid leukemia (AML) patients. We also investigated the therapeutic value of PPARγ stimulation using pioglitazone in the AML-derived U937 cell line. METHODS: The blood samples from 30 patients diagnosed with non-M3 AML as well as 10 healthy individuals were collected and the mRNA expression levels of PPARγ and PTEN were evaluated. Additionally, we used trypan blue assay, MTT assay, and flow cytometry analysis to evaluate the anti-leukemic effects of pioglitazone on U937 cells. RESULTS: While PTEN was significantly downregulated in AML patients as compared to the control group, the expression of PPARγ was increased in the patients' group. The expression level of PPARγ was also negatively correlated with PTEN; however, it was not statistically significant. Besides, PPARγ stimulation using pioglitazone reduced survival and proliferative capacity of U937 cells through inducing apoptosis and suppression of cell transition from the G1 phase of the cell cycle. CONCLUSION: The results of the present study shed more light on the importance of PPARγ and its stimulation in the therapeutic strategies of AML.
30
Lisa Patel, Ian Pass, Phil Coxon et al. · Current Biology · 2001 · 363 citations · Full text
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Stéphane Prost, Francis Relouzat, Marc Spentchian et al. · Nature · 2015 · 258 citations · Full text
Medicine, Cell Biology, Pharmacology +12
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
Bo Shen, Eagle SH Chu, G. Zhao et al. · British Journal of Cancer · 2012 · 127 citations · Full text
Medicine, Oncology, Pharmacology +15
Thiazolidinediones as anti-cancer agents.
Carmelo Blanquicett, Jesse Roman, C. Michael Hart · PubMed · 2008 · 123 citations
Medicine, Oncology, Pharmacology +14